Clinical research conductor ICON Plc downplayed impacts from demand softness from the pharmaceutical and biotechnology industries, surprising investors with a $100 million revenue shortfall that led ...

ICON Equity Income Fund earns an Average Process ... Over a 10-year period, this share class undershot its average peer by 1.4 percentage points annualized. It also trailed the category benchmark ...

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

BofA analyst Michael Ryskin lowered the firm’s price target on Icon (ICLR) to $255 from $270 and keeps a Buy rating on the shares. The firm ...

The user of the website is referred to as "you" and "your". By posting on our share chat boards you are agreeing to the following: If you are going to post non-English, please also post an English ...